Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Iloprost therapy in systemic sclerosis].

G Bali1, E Aberer

  • 1Universitätsklinik für Dermatologie und Venerologie, Karl-Franzens Universität Graz, Graz, Austria.

Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete
|September 5, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dermatology Life Quality Index (DLQI) score bands are applicable to DLQI-Relevant (DLQI-R) scoring.

Journal of the European Academy of Dermatology and Venereology : JEADV·2020
Same author

Facets of shame are differently expressed in dermatological disease: a prospective observational study.

The British journal of dermatology·2020
Same author

DLQI-R scoring improves the discriminatory power of the Dermatology Life Quality Index in patients with psoriasis, pemphigus and morphea.

The British journal of dermatology·2019
Same author

Large Variability of Frequency and Type of Physical Therapy in Patients in the German Network for Systemic Sclerosis.

Arthritis care & research·2019
Same author

Association between quality of life and clinical characteristics in patients with morphea.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2018
Same author

European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes.

Journal of the European Academy of Dermatology and Venereology : JEADV·2017
Same journal

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
Same journal

[Viral infections of the skin].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
Same journal

[Viral exanthems in children].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
Same journal

[Erratum to: Digital health applications and data protection].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
Same journal

[Virus-induced exanthems in returning travellers].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
Same journal

[Venous ulcus cruris-Surgical treatment].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
See all related articles

Iloprost, a prostacyclin analogue, shows promise in treating systemic sclerosis by improving Raynaud attacks and digital ulcers. Intermittent monthly infusions may maintain treatment effects for this challenging autoimmune disease.

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Systemic sclerosis is a complex autoimmune disease with unknown etiology impacting multiple organ systems.
  • Current management strategies for systemic sclerosis offer limited success.
  • Iloprost, a prostacyclin analogue, possesses antifibrotic properties relevant to systemic sclerosis pathogenesis.

Purpose of the Study:

  • To review published data on the optimal dosage and duration of iloprost treatment for systemic sclerosis.
  • To evaluate the efficacy of iloprost in managing key symptoms and complications of systemic sclerosis.

Main Methods:

  • Analysis of published data from three distinct studies on iloprost therapy.
  • Assessment of treatment outcomes based on Raynaud attack frequency/intensity, digital ulcer healing, and digital perfusion.

Related Experiment Videos

Main Results:

  • A 5-day course of iloprost at 1-2 ng/kg/min significantly improved Raynaud attacks, digital ulcers, and perfusion.
  • Therapeutic benefits were observed for approximately one month post-treatment.
  • Monthly repeated infusions helped maintain the observed treatment effects.

Conclusions:

  • Intermittent iloprost therapy may improve or stabilize systemic sclerosis.
  • Further long-term studies are warranted to validate the efficacy of this treatment regimen.